National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 835595

Case Details

VAERS ID: 835595 (history)  
Form: Version 2.0  
Age:   
Sex: Unknown  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 0000-00-00
Entered: 2019-09-24
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPVX: HPV (NO BRAND NAME) / UNKNOWN MANUFACTURER - / 1 - / OT

Administered by: Other       Purchased by: ?
Symptoms: Condition aggravated, Death, Dizziness, Malaise, Malaria, Rash, Typhoid fever
SMQs:, Anaphylactic reaction (broad), Anticholinergic syndrome (broad), Vestibular disorders (broad), Hypersensitivity (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Opportunistic infections (broad)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Malaria (receieved treatment for malaria a few days after receiving her HPV vaccine); Typhoid (receieved treatment for typhoid a few days after receiving her HPV vaccine)
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC Split Type: NGGLAXOSMITHKLINENG2019EM

Write-up: Malaria; Typhoid; General malaise; Dizziness; Her conditioned worsened before she passed away; Rash; This case was reported by a consumer and described the occurrence of rash in a female patient who received HPV 16-18 (HPV vaccine) for prophylaxis. Concurrent medical conditions included malaria (receieved treatment for malaria a few days after receiving her HPV vaccine) and typhoid (receieved treatment for typhoid a few days after receiving her HPV vaccine). On an unknown date, the patient received the 1st dose of HPV vaccine (intramuscular). On an unknown date, couple of hours after receiving HPV vaccine, the patient experienced rash (serious criteria death), malaria (serious criteria hospitalization and GSK medically significant), typhoid (serious criteria hospitalization and GSK medically significant), general malaise (serious criteria hospitalization), dizziness (serious criteria hospitalization) and condition aggravated (serious criteria hospitalization). On an unknown date, the outcome of the rash was fatal and the outcome of the malaria, typhoid and condition aggravated were unknown and the outcome of the general malaise and dizziness were not recovered/not resolved. The reported cause of death was rash. It was unknown if the reporter considered the rash, malaria, typhoid, general malaise, dizziness and condition aggravated to be related to HPV vaccine. Additional details were provided as follows: The reported information received was from a third party, not a direct relative of the patient. The age at vaccination was not reported. The patient experienced rash a few hours after receiving HPV vaccine. On visiting the hospital the next day after receiving HPV vaccine,the patient''s reactions were mild and would soon stop. Few days after receiving HPV vaccine, the patient complained of general malaise and dizziness and was admitted in a private hospital and treated for malaria and typhoid. She was later taken to a general hospital where her conditioned worsened before she passed away.; Reported Cause(s) of Death: Rash


New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?IDNUMBER=835595


Copyright © 2020 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166